Journal
MOLECULAR PHARMACEUTICS
Volume 14, Issue 7, Pages 2390-2399Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00295
Keywords
alginate; microencapsulation; hyaluronic acid; mesenchymal stem cells
Funding
- University of the Basque Country UPV/EHU [UFI11/32, EHUA 16/06]
- Basque Country Government (Grupo de Investigacion Consolidado del Sistema Universitario Vasco) [IT428-10]
Ask authors/readers for more resources
The potential clinical application of alginate cell microencapsulation has advanced enormously during the past decade. However, the 3D environment created by alginate beads does not mimic the natural extracellular matrix surrounding cells in vivo, responsible of cell survival and functionality. As one of the most frequent macromolecules present in the extracellular matrix is hyaluronic acid, we have formed hybrid beads with alginate and hyaluronic acid recreating a closer in vivo cell environment. Our results show that 1% alginate-0.25% hyaluronic acid microcapsules retain 1.5% alginate physicochemical properties. Moreover, mesenchymal stem cells encapsulated in these hybrid beads show enhanced viability therapeutic protein release and mesenchymal stem cells' potential to differentiate into chondrogenic lineage. Although future studies with additional proteins need to be done in order to approach even more the extracellular matrix features, we have shown that hyaluronic acid protects alginate encapsulated mesenchymal stem cells by providing a niche-like environment and remaining them competent as a sustainable drug delivery system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available